Compare MVST & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVST | SPRY |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 829.3M |
| IPO Year | N/A | 2020 |
| Metric | MVST | SPRY |
|---|---|---|
| Price | $2.36 | $8.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 2.2M | 936.8K |
| Earning Date | 01-01-0001 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $24.19 | $109.11 |
| Revenue Next Year | $17.70 | $91.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.09 | $6.66 |
| 52 Week High | $7.12 | $18.63 |
| Indicator | MVST | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 41.71 |
| Support Level | $2.07 | $8.61 |
| Resistance Level | $2.40 | $10.44 |
| Average True Range (ATR) | 0.12 | 0.46 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 64.29 | 40.74 |
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.